SCPS.OQ
Latest Trade
7.79USDChange
--(--)Today's Range
-
--52 Week Range
-
47.85As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 7.79 |
|---|---|
Open | -- |
Volume | -- |
3M AVG Volume | 3.25 |
Today's High | -- |
Today's Low | -- |
52 Week High | 47.85 |
52 Week Low | 5.44 |
Shares Out (MIL) | 15.73 |
Market Cap (MIL) | 122.99 |
Forward P/E | -- |
Dividend (Yield %) | -- |
Scopus Biopharma Announces Pricing Of Initial Public Offering
Scopus BioPharma Inc. is a biotechnology company. The Company is focused on developing therapeutics targeting serious diseases. The Company’s lead program targets immuno-oncology gene therapy for the treatment of multiple cancers. Its lead development program is CpG-STAT3siRNA (CO-sTiRNA), which is in Phase I clinical trial, is a STAT3 inhibitor gene therapy. CO-sTiRNA is developed for the treatment of B-cell non-Hodgkins lymphoma. It also stimulates TLR9 receptors to activate the body’s immune defense to kill cancer cells. Its second development program is in pre-clinical stage MRI-1867, a cannabinoid receptor mediating compound for the treatment of systemic sclerosis. MRI-1867 is a small molecule that is an inverse agonist of the cannabinoid-1 receptor (CB1), as well as an inhibitor of the inducible nitric oxide synthase (iNOS) system.
Industry
Biotechnology & Drugs
Contact Info
420 Lexington Ave Rm 300
NEW YORK, NY
10170-0399
United States
+1.212.4792513
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | -- |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | -- |
LT Debt To Equity (MRQ) | -- |
Return on Investment (TTM) | -- |
Return on Equity (TTM) | -791.21 |
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.